Coya Therapeutics, Inc.
COYA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for COYA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · COYA
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and autoimmune diseases, with its lead program in ALS and cash runway into H2 2027.
Key risk: Capital needs
BioSniper Score
Based on 5 of 6 signals
Market Cap
$107.7M
Cash Runway
18.0 moLead Asset
COYA 302 (Phase 2/Phase 3)
Next Catalyst
Phase2_Topline · Mar 31, 2027Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 6 clinical trials · 3 catalysts for Coya Therapeutics, Inc..
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and autoimmune diseases, with its lead program in ALS and cash runway into H2 2027.
- Cash and equivalents of $43.2M as of 2026-06-30 [sec].
- Total revenue of $0.2M and net loss of -$6.6M for the period ending 2026-06-30 [sec].
- Cash runway guidance into the second half of 2027 and past the projected topline for the ALSTARS trial [sec · filed 2026-01-30].
- Company expects to fund accelerated commercial readiness plans with no impact to cash runway [sec · filed 2026-01-30].
What works
- Cash runway extends into H2 2027, past a key clinical readout (ALSTARS topline) [sec · filed 2026-01-30].
- Company is advancing commercial readiness plans, indicating confidence in pipeline progress [sec · filed 2026-01-30].
What to weigh
- Company has minimal revenue ($0.2M) and is operating at a net loss, requiring ongoing financing [sec].
- The company acknowledges it will need to raise substantial additional capital to support operations and growth [sec_mda · as of 2026-03-16].
- Clinical-stage biotech with no approved products; success depends on unproven clinical trial outcomes [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Cash runway extends into H2 2027 and past ALSTARS topline.
“The Company reiterates its cash runway guidance into the second half of 2027 and past the projected topline for ALSTARS trial.”
SEC filings · January 30, 2026
Company expects to fund accelerated commercial readiness plans.
“The Company expects the proceeds from the Offering to allow it to fund its now accelerated commercial readiness plans with no impact to its cash runway guidance.”
SEC filings · January 30, 2026
Company will need to raise substantial additional capital.
“We will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy.”
SEC MD&A · March 16, 2026
Catalyst timeline
- 2027-03-31 · Phase2_Topline · alstars — Phase 2 Readout: alstars — Topline results from the Phase 2 ALSTARS trial in ALS.
- 2027-07-01 · Phase3_Topline — Phase 3 Topline: Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study With Additional — Topline results from a Phase 2/3 randomized, double-blind, placebo-controlled study.
- 2027-12-31 · Phase2_Topline — Phase 2 Readout: pipeline candidate — Topline results from a Phase 2 study of another pipeline candidate.
Risks & what to watch (3)›
Key risks
- Capital needs — Company will need to raise substantial additional capital to support operations and growth [sec_mda · as of 2026-03-16].
- Clinical-stage dependency — No approved products; success depends on unproven clinical trial outcomes [sec_mda · as of 2026-08-11].
- Minimal revenue — Revenue is negligible ($0.2M) with ongoing net losses [sec].
What to watch
- Phase 2 topline data from the ALSTARS trial, expected in Q1 2027 [catalyst timeline].
- Phase 3 topline data from a randomized, double-blind, placebo-controlled study, expected in Q3 2027 [catalyst timeline].
- Phase 2 topline data for another pipeline candidate, expected in Q4 2027 [catalyst timeline].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Coya Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Coya Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
18.0 months
D/E 0.09 · 0% dilution
Lead: Phase 2/Phase 3
2 candidates
3 upcoming, next in ~213d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
54
Total value held
$21.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,689,826 | $6.7M |
| alyeska investment group, l.p. | 800,000 | $3.2M |
| prosight management, lp | 420,360 | $1.7M |
| private management group inc | 369,096 | $1.5M |
| geode capital management, llc | 233,402 | $920K |
| marshall wace, llp | 225,792 | $890K |
| vanguard fiduciary trust co | 139,886 | $551K |
| renaissance technologies llc | 103,964 | $410K |
| prelude capital management, llc | 101,330 | $399K |
| jbf capital, inc. | 100,006 | $394K |
Showing top 10 of 54 institutional holders of Coya Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 3.7%
- Days to cover
- 5.6
- Shares short
- 825,568
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
COYA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Coya Therapeutics, Inc.?
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and autoimmune diseases, with its lead program in ALS and cash runway into H2 2027.
What is Coya Therapeutics, Inc.'s lead drug candidate?
Coya Therapeutics, Inc.'s most advanced tracked candidate is COYA 302 (Phase 2/Phase 3) for Amyotrophic Lateral Sclerosis (ALS).
What is Coya Therapeutics, Inc.'s next catalyst?
Coya Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: alstars" — expected March 31, 2027.
Who is the CEO of Coya Therapeutics, Inc.?
Dr. Arun Swaminathan Ph.D. is the chief executive officer of Coya Therapeutics, Inc. (COYA).
Where is Coya Therapeutics, Inc. headquartered?
Coya Therapeutics, Inc. (COYA) is headquartered in Houston, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.